胸心外科

订阅

MedSci主页 / 所有栏目 / 胸心外科

药物支架用于裸支架术后再狭窄及动脉瘤（图）

2015-12-02 网络 MedSci原创

药物支架医学图片
关注

药物支架用于裸支架术后再狭窄及动脉瘤

药物支架用于裸支架术后再狭窄及动脉瘤

药物支架用于裸支架术后再狭窄及动脉瘤

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2019244, encodeId=06e0201924499, content=<a href='/topic/show?id=e9d25e1068b' target=_blank style='color:#2F92EE;'>#支架术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57106, encryptionId=e9d25e1068b, topicName=支架术后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 19 18:14:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080831, encodeId=c1d0208083140, content=<a href='/topic/show?id=53fa5e10578' target=_blank style='color:#2F92EE;'>#支架术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57105, encryptionId=53fa5e10578, topicName=支架术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 07 19:14:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667214, encodeId=2d71166e214ed, content=<a href='/topic/show?id=9c1c8e76228' target=_blank style='color:#2F92EE;'>#药物支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87762, encryptionId=9c1c8e76228, topicName=药物支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b6926126087, createdName=Boyinsh, createdTime=Wed Jan 13 13:14:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486189, encodeId=66fa1486189f1, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 04 00:14:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2016-04-19 gujh

    #支架术后#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2019244, encodeId=06e0201924499, content=<a href='/topic/show?id=e9d25e1068b' target=_blank style='color:#2F92EE;'>#支架术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57106, encryptionId=e9d25e1068b, topicName=支架术后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 19 18:14:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080831, encodeId=c1d0208083140, content=<a href='/topic/show?id=53fa5e10578' target=_blank style='color:#2F92EE;'>#支架术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57105, encryptionId=53fa5e10578, topicName=支架术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 07 19:14:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667214, encodeId=2d71166e214ed, content=<a href='/topic/show?id=9c1c8e76228' target=_blank style='color:#2F92EE;'>#药物支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87762, encryptionId=9c1c8e76228, topicName=药物支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b6926126087, createdName=Boyinsh, createdTime=Wed Jan 13 13:14:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486189, encodeId=66fa1486189f1, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 04 00:14:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2016-05-07 qindq

    #支架术#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2019244, encodeId=06e0201924499, content=<a href='/topic/show?id=e9d25e1068b' target=_blank style='color:#2F92EE;'>#支架术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57106, encryptionId=e9d25e1068b, topicName=支架术后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 19 18:14:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080831, encodeId=c1d0208083140, content=<a href='/topic/show?id=53fa5e10578' target=_blank style='color:#2F92EE;'>#支架术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57105, encryptionId=53fa5e10578, topicName=支架术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 07 19:14:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667214, encodeId=2d71166e214ed, content=<a href='/topic/show?id=9c1c8e76228' target=_blank style='color:#2F92EE;'>#药物支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87762, encryptionId=9c1c8e76228, topicName=药物支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b6926126087, createdName=Boyinsh, createdTime=Wed Jan 13 13:14:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486189, encodeId=66fa1486189f1, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 04 00:14:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2016-01-13 Boyinsh

    #药物支架#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2019244, encodeId=06e0201924499, content=<a href='/topic/show?id=e9d25e1068b' target=_blank style='color:#2F92EE;'>#支架术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57106, encryptionId=e9d25e1068b, topicName=支架术后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 19 18:14:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080831, encodeId=c1d0208083140, content=<a href='/topic/show?id=53fa5e10578' target=_blank style='color:#2F92EE;'>#支架术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57105, encryptionId=53fa5e10578, topicName=支架术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat May 07 19:14:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667214, encodeId=2d71166e214ed, content=<a href='/topic/show?id=9c1c8e76228' target=_blank style='color:#2F92EE;'>#药物支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87762, encryptionId=9c1c8e76228, topicName=药物支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b6926126087, createdName=Boyinsh, createdTime=Wed Jan 13 13:14:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486189, encodeId=66fa1486189f1, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 04 00:14:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2015-12-04 12498f1em10(暂无昵称)

    #再狭窄#

    0

相关资讯

TCT 2015全新揭晓临床试验：三项来自中国

2015年美国经导管心血管治疗学会议（TCT）将于10月11日-15日在旧金山召开，作为全球心血管介入医学领域最具影响力的盛会，每年TCT最新揭晓临床试验（LBCT）专场都有“重磅”研究发布。今年全世界有超过100项研究申请LBCT，经过初筛51项入选专家“盲法”评审过程，最终有12项前瞻性、大规模、随机对照临床试验入选，将在主会场发布。令人兴奋的是，在这12项试验中将有3项来自中国，分别为阜外医

2014欧洲心脏病学会五大指南亮点

在2014年欧洲心脏病学会(ESC)年会上，新发布的五大指南亮点颇多，备受瞩目。现邀请专家撰文，告诉医生们应重点了解哪些内容。 2014ESC/ESA 非心脏手术心血管评估和治疗指南 新版指南指出，术前应对患者围术期心血管风险进行系统的个体化评估，内容包括评估手术本身引起的心血管风险及不同手术方式之间的心血管风险差异，评估患者当前心血管状态等。建议根据评估结果采取相应的预

AHA 2014：郭艺芳：冠脉药物支架术后双抗治疗需多久？

按照现行指南建议，冠状动脉植入药物支架术后患者需要接受为期12个月阿司匹林与氯吡格雷（或其他噻吩吡啶类药物）双联抗血小板治疔。继续延长双抗时间是否能继续获益？缩短双抗时间是否会增加支架内栓风险？这些问题均受到广泛关注，但迄今尚无明确答案。本届AHA年会期间将公布3项相关研究，其中双联抗血小板研究（DAPT）与药物支架术后6个月双联抗血小板治疗安全性和有效性研究（ISAR-SAFE）最值得关注，

吕树铮教授谈如何预防DES支架再狭窄

       导语：支架膨胀不全、支架贴壁不良等机械因素是DES支架内再狭窄的常见原因，吕树铮教授为大家谈如何预防DES支架再狭窄。 吕树铮教授     药物支架发生再狭窄是否行常规性IVUS检查     从目前临床工作当中，药物支架发生再狭窄的概率比较低了，也就是5%～8%

波士顿科学公司两款心脏介入治疗产品再获全新临床研究数据支持

SYNERGY™支架系统及LOTUS™瓣膜系统的安全性与有效性再次得到验证 中国上海，2014年6月16日 ——2014年欧洲介入心脏病大会（EuroPCR）在近日召开，会上公布的最新临床数据进一步证实了波士顿科学（交易代码：BSX）SYNERGY™支架系统与Lotus™瓣膜系统的安全性与有效性[1]。 EVOLVE研究三年临床随访数据显示SYNERGY™支架系统具卓越的安全性

郭艺芳：2014年心血管病学领域要闻盘点

一、中国心力衰竭防治指南更新 更新要点包括： （1）醛固酮拮抗剂适用人群扩大至所有有症状的心衰患者； （2）伊伐布雷定得到肯定与推荐； （3）增加了急性心力衰竭的防治建议； （4）心脏再同步化治疗的适用人群扩大至NYHA ll级的慢性心力衰竭患者； （5）推荐应用BNP/NT-proBNP动态监测评估慢性心力衰竭治疗效果。 二、中国胆固醇教育计划血脂异